20/05/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041NextNext post:AB Science announces the settlement delivery of its latest capital increase for €1.8 millionRelated PostsAB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025
New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
